Harvest One Cannabis Stock (TSXV: HVST) (OTC: HRVOF) - Investor Dashboard

➔ Harvest One Cannabis
TSX Venture Exchange: HVST
Sector: Healthcare
Industry: Legal Cannabis
Country: Canada
Employees:  26
Established: 2015
CEO: Andreas Gedeon


Fiscal Year-End: June
License Renewal Month: June
Licenses: 1
Licensed Capacity:  100KG
Number of Patients: 0
Headquarters: Vancouver, BC

Financials (09/30/17)

Cash on hand: $12.16mm
Fixed Investment: $8.40mm
Shareholders’ Equity: $21.95mm
Revenues – Last Quarter: $175K
Adj. Gross Margin : -17.5%
EPS : -$0.02

Capital Structure (01/31/18)

Last Financing:  22.11mm Units at $1.82
Basic Shares: 111.3mm
Warrants: 50.1mm
Options: 8.1mm
Diluted Shares: 193.3mm

Company Brief

Harvest One is a holding company that owns Canadian ACMPR licensed producer United Greeneries and Swiss medical cannabis brand Satipharm. United Greeneries received its cultivation license in June 2016 and is focused on expanding the capacity at it Duncan Facility from about 1000kg per year to about 50,000kg per year to serve both the medical and recreational markets. The company, which is targeting production capacity of 8500kg by the end of 2017, also owns a 62K sq. ft. facility on over 18 acres in Lucky Lake, Saskatchewan that has submitted an ACMPR application. The company closed a $25mm financing transaction in February to help fund its capacity expansion.

Satipharm, which is generating revenue, focuses on oral delivery technologies. It has been producing Gelpell ® Microgel Capsules, a pharmaceutical grade product with GMP production,  since May 2015. The company is focusing initially on Germany and Poland and will be entering other EU countries this year. Satipharm plans to export Gelpell ® Microgel products into the Canadian ACMPR market and the Australian market and also plans to license or introduce products into regulated cannabis markets internationally.

Featured Video

A peak into United Greeneries’ flagship facility on Vancouver Island in Canada. The facility was the 30th operation that got licensed under the Canadian MMPR (now ACMPR) in June 2016 and started growing operations in December 2016. There are currently 33 different genetic varieties of cannabis in production, the first harvest is expected in March 2017.

HVST shareholders will have significant exposure to two of the largest commercial opportunities in the global cannabis sector


United Greeneries is a Canadian ACMPR Licensed Producer and will be HVST’s horticultural arm and recreational brand.

  • ACMPR (MMPR) Licensed Producer Duncan Facility
  • Current capacity of ~1,000 kg/year
  • Immediate greenhouse expansion plan – capacity growth to ~8,500 kg/year in 12 months (Phase I)
  • 3-phase modular expansion up to ~51,000 kg/year total capacity
  • ACMPR applicant Lucky Lake (~12,000 kg/year facility currently in security clearance stage)

Satipharm is specialized in the development and manufacturing of cannabis- based health products and will be the company’s medical and health brand

  • Flagship Gelpell ® Microgel Capsules to lead growth
    • Near-term growth from supplement sales in EU
    • Mid-term growth from entry into regulated markets (Canada, Australia, etc.)
    • Significant growth opportunities globally
  • Global exclusive rights to Gelpell ® on cannabis applications; Gelpell Phase 1
  • Growing portfolio of delivery technology IP

Meet the CEO

A brief Q&A with Harvest One CEO Andreas Gedeon

Focused on recreational and medical markets
HVST will be a well-financed, growth- oriented cannabis company focused on supplying Canadian and international medical and recreational cannabis markets through two distinct operating brands:

United Greeneries
Canadian ACMPR Licensed Producer with focus on large-scale horticultural operations for the upcoming Canadian recreational cannabis market

International medical cannabis brand with focus on oral delivery technologies for strategic entry in emerging medical cannabis markets and the existing medical cannabis market in Canada


  • Recreational and medical focus
  • Two Brands
    • United Greeneries focused on large-scale production
    • Satipharm focused on oral delivery technologies
  • Serving Canada and international markets

Growth Strategy

  • Increase Duncan Facility capacity to 50,000 kg in three phases
  • Finalize wholesale agreements and begin distribution with Health Canada approval
  • Complete Lucky Lake Facility ACMPR application process
  • Expand Satipharm distribution in Europe in near-term and prepare to export to Canada & Australia


  • Two potential production facilities
  • Not investing in competitive medical distribution in Canada
  • In-house QA/QC laboratory
  • Technology-driven portfolio of health products
  • Active in European CBD markets

Institutional Analyst Coverage

Curated Stories & News

Visit Harvest One Cannabis, Inc.
at www.harvestone.com.

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Harvest One Cannabis, Inc., is a client of NCV Media, LLC. Read our full disclaimer.